Cited by 164Pancreatic and Hepatic Oncology ResearchCancer Cells and MetastasisPancreatic function and diabetes

Successful creation of pancreatic cancer organoids by means of EUS-guided fine-needle biopsy sampling for personalized cancer treatment

Open access
Tiriac, Herve, Bucobo, Juan Carlos, Tzimas, Demetrios, Grewel, Suman, Lacomb, Joseph F., Rowehl, Leahana M., Nagula, Satish, Wu, Maoxin +9 more·2018·Gastrointestinal Endoscopy

Abstract

Background and aims Pancreatic cancer organoids are tumor models of individualized human pancreatic ductal adenocarcinoma (PDA), created from surgical specimens and used for personalized treatment strategies. Unfortunately, most patients with PDA are not operative candidates. Creation of human PDA organoids at the time of initial tumor diagnosis is therefore critical. Our aim was to assess the feasibility of creating human PDA organoids by EUS fine-needle biopsy (EUS-FNB) sampling in patients with PDA.Methods In this prospective clinical trial in patients referred to evaluate a pancreatic mass, EUS-FNA was performed for initial onsite diagnosis. Two additional needle passes were performed with a 22-gauge FNB needle for organoid creation. Primary outcome was successful isolation of organoids within 2 weeks of EUS-FNB sampling (P0, no passages), confirmed by organoid morphology and positive genotyping.Results Thirty-seven patients with 38 PDA tumors were enrolled. Successful isolation of organoids (P0) was achieved in 33 of 38 tumors (87%). Establishment of PDA organoid lines for ≥5 passages of growth (P5, five passages) was reached in 25 of 38 tumors (66%). In the single patient with successful P5 FNB sampling-derived and P5 surgically derived organoids, there was identical matching of specimens. There were no serious adverse events. Two patients developed bleeding at the EUS-FNB puncture site requiring hemostasis clips.Conclusions Pancreatic cancer organoids can be successfully and rapidly created by means of EUS-FNB sampling using a 22-gauge needle at the time of initial diagnosis. Successful organoid generation is essential for precision medicine in patients with pancreatic cancer in whom most are not surgically resectable. (Clinical trial registration number: NCT03140592.).

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.gie.2017.12.032

Cites

29 of 29 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Tumor tissue from biopsies or surgical resections is typically processed similarly to normal tissue to isolate tumor cells for organoid growth.

    “Tumor tissue, derived from either biopsies or surgical resections, is also typically processed akin to normal tissue to isolate tumour cells to grow as organoids16,49–51.”

    From Organoids (2022) · cites this paper as [50]

    The Methods (Organoid Generation and Maintenance; page unavailable) describe dissociating fine-needle biopsy tissue and growing the resulting cells and tissue fragments as organoids; they also say organoids were made from surgically resected tumors. The paper does not compare this processing with normal-tissue processing or establish that the approach is typical across tumor types. (LLM, conf=0.85)

    Experimental — accuracy not yet measured
  • Tumor cells from liquid samples such as peripheral blood, ascites, and pleural effusions can be used as starting material to generate organoids.

    “Tumor cells isolated from liquid samples such as peripheral blood52, ascites50,53, and pleural effusions54 can also be used as starting material to generate organoids.”

    From Organoids (2022) · cites this paper as [50]

    Citation 53 is attached to ascites. The Methods (Organoid Generation and Maintenance; page unavailable) describe organoids grown from fine-needle biopsy tissue and surgically resected tumors, but our copy does not address generating organoids from ascites. Searches for ascites and other liquid samples found no supporting passage. (LLM, conf=0.76)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

1 of the 30 references couldn’t be matched to a known paper.

Research works printed but not linked: 1

  1. [27]Nagula S, Pourmand K, Aslanian H, Comparing EUS-fine needle aspiration and EUS-fine needle biopsy for solid lesions: A multicenter, randomized trial. Clin Gastroenterol Hepatol 2017; [Epub ahead of print], PMID: 28624647. 28624647

Cited by

Sorted by citations

Authors
Tiriac, H., Bucobo, J. C., Tzimas, D., Grewel, S., Lacomb, J. F., Rowehl, L. M., Nagula, S., Wu, M., Kim, J., Sasson, A., Vignesh, S., Martello, L., Munoz-Sagastibelza, M., Somma, J., Tuveson, D. A., Li, E., & Buscaglia, J. M.
Affiliations
  • Stony Brook School (US)
  • SUNY Downstate Health Sciences University (US)
  • Cold Spring Harbor Laboratory (US)
Corresponding author
Buscaglia, Jonathan M.
Venue
Gastrointestinal Endoscopy
Publisher
Elsevier BV
Published
2018-06
Volume
87
Issue
6
Pages
1474-1480
ISSN
0016-5107 (ISSN-L)
OpenAlex
W2608725539
Cited by
164
References
30
Citations by year
2026: 7 · 2025: 10 · 2024: 20 · 2023: 12 · 2022: 31 · 2021: 26 · 2020: 30 · 2019: 17 · 2018: 9 · 2017: 2
FWCI
7.69
Type
journal article
Language
en
Open access
Locations
  • Gastrointestinal Endoscopy (publishedVersion)
  • PubMed (publishedVersion)
  • PubMed Central (acceptedVersion)
  • Cold Spring Harbor Laboratory Institutional Repository (Cold Spring Harbor Laboratory) (submittedVersion)
Funders
  • Boston Scientific Corporation
  • Stony Brook University
  • National Institutes of Health (5p30ca045508-35)
  • National Cancer Institute (P20CA192996, P50CA101955, R01CA188134, U10CA180944, P20CA192994, U01CA168409, P30-CA045508, R01CA190092)
Topics
  • Health Sciences › Medicine › Oncology › Pancreatic and Hepatic Oncology Research
  • Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
  • Health Sciences › Medicine › Surgery › Pancreatic function and diabetes
Keywords
pancreatic ductal adenocarcinoma, pancreatic cancer organoids, EUS-guided fine-needle biopsy, precision oncology, precision medicine, unresectable pancreatic cancer, endoscopic ultrasound-guided fine-needle aspiration
MeSH terms
Aged, Aged, 80 and over, Female, Humans, Male, Middle Aged, Organoids, Pancreatic Neoplasms, Tumor Cells, Cultured, Carcinoma, Pancreatic Ductal, Tissue Culture Techniques, Precision Medicine, Endoscopic Ultrasound-Guided Fine Needle Aspiration

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review